Re: La Câlin Mp3 Download
Oleta Blaylock
Joining is free and without any commitments. The Clin-STAR Database features unique functions to search and visualize how the broad aging research community is connected with clinician-investigators from any discipline or level of seniority, starting as early as medical students. The database allows users to easily identify and contact investigators for transdisciplinary research collaborations and mentoring opportunities.
The Clin-STAR Inflammation Interest Group was created by a group of GEMSSTAR Scholars after participating in the 2021 Clin-STAR Annual Meeting. The intent of this interest group is to offer a small virtual, interactive, peer support forum to learn from both senior guest researchers and each other about inflammation and aging research. Junior clinician scientists from different specialties and disciplines are welcomed.
The intent of the Clin-STAR Frailty Research Interest Group is to offer a virtual forum to learn from invited guest researchers to share experiences and expertise on frailty and aging research, with ample time for Q&A. Some meetings serve as more of a forum to share research projects and network. Clinician scientists from different specialties and disciplines are welcomed.
The Clin-STAR Delirium Interest Group was initiated by GEMSSTAR Scholars who are passionate about studying delirium, who met at the 2022 Clin-STAR Annual Meeting. The goals of the interest group are to provide a supportive forum for Early-Stage Investigators to network across clinical disciplines, to share works in progress, learn from senior experts in the field, and collaborate on scholarly projects. The group will work synergistically with the NIDUS network and the American Delirium Society. Clinician scientists from different specialties and disciplines are welcomed.
The Clin-STAR Exercise and Lifestyle Medicine Interest Group has been formed by members of the Clin-STAR community for those with aging research interests in exercise, function, nutrition, sleep, etc. The goals of the group are to provide a supportive forum for Early-Stage Investigators to network across clinical disciplines to share research works in progress, review specific aims by members, learn from senior experts in the field, and perhaps collaborate on a group project such as a webinar, paper or symposium. Clinician scientists from different specialties and disciplines are welcomed.
The goals of the group are to provide a supportive forum for early-stage surgical and anesthesia investigators to network across clinical specialties, to share clinical/research challenges through consultancies, discuss funding, and research works in progress, and to learn from peers and senior experts in the field.
Programming depends on group interests and includes members sharing works in progress, guest researchers, consultancies, and may include a group paper or symposium. Clinician scientists from different specialties and disciplines are welcomed. Many participants are interested in health disparities and community engaged research and the group welcomes new members!
The goal of the Clin-STAR Biology of Aging Research Interest Group is to provide a forum within the Clin-STAR community to discuss and focus on biological mechanisms that contribute to aging and age-associated diseases. These include the Hallmarks of Aging (inflammation, genomic instability, cellular senescence, etc), as well as other unidentified cellular and molecular mechanisms. The group is open to all who are interested in discussing and learning more about the Biology of Aging. We hope that this forum will lead to collaborations that will ultimately advance research in the fields of Aging Biology and Translational Geroscience.
To access document links to Clin-STAR Interest Group Projects, visit this page. The page is password-protected; please reach out to and...@afar.org if you are a group member who needs access and you do not have the password.
Riley et al. investigated whether preexisting maternal immunity to AAV vectors and Cas9 endonuclease impairs in utero gene editing. In mice, maternal anti-AAV IgG impaired fetal gene editing in a titer-dependent fashion, while maternal humeral and cellular immunity to Cas9 did not. In human pregnancy, maternal-fetal transmission of anti-AAV IgG was found to be inefficient in mid-gestation, when in utero gene editing would be performed clinically. Image credit: John Muhlenkamp.
Although cancer has long been considered a genetic disease, increasing evidence shows that epigenetic aberrations play a crucial role in affecting tumor biology and therapeutic response. The dysregulated epigenome in cancer cells reprograms the immune landscape within the tumor microenvironment, thereby hindering antitumor immunity, promoting tumor progression, and inducing immunotherapy resistance. Targeting epigenetically mediated tumor-immune crosstalk is an emerging strategy to inhibit tumor progression and circumvent the limitations of current immunotherapies, including immune checkpoint inhibitors. In this Review, we discuss the mechanisms by which epigenetic aberrations regulate tumor-immune interactions and how epigenetically targeted therapies inhibit tumor progression and synergize with immunotherapy.
Designing strategies to target cell proliferation has been a priority of cancer researchers for decades. However, targeting the secretory programs of transformed cells can influence other cancer features such as cell survival, migration, and communication with the tumor stroma. In this issue of the JCI, Tan and colleagues describe functional cooperativity between the Golgi-resident proteins Golgi integral membrane protein 4 (GOLIM4) and ATPase secretory pathway Ca2+ transporting 1 (ATP2C1) in the coordination of a secretory program in 3q-amplified cancers. Targeting these tumors with manganese (Mn2+) promoted GOLIM4 degradation and imposed a secretory blockade that impaired tumor progression and stromal cell recruitment in mice. These findings highlight the secretory program as a therapeutic target in 3q-amplified malignancies and provide a promising strategy to treat tumor progression.
Bone fracture healing is a complex process with distinct phases: the inflammatory phase, the soft and hard callus formation, and the remodeling phase. In older individuals, bone healing can be delayed or disturbed, leading to non-union fractures at worst. The initial healing phases require communication between immune cells and osteoprogenitor cells. However, senescence in these cell types impedes fracture healing by unknown mechanisms. In this issue of the JCI, Saul et al. showed that two distinct senescent p21-expressing cell populations, an osteochondroprogenitor cell and a neutrophil subpopulation, intrinsically impair fracture healing in mice irrespective of age. Genetic ablation of p21-positive cells accelerated fracture healing, while removal of a different senescent cell population, p16-positive cells, made no difference. Conceptually, this view of senescence in fracture healing with a spotlight on osteoimmune cross-talk provides a promising rationale for therapies to boost bone repair at all ages.
Obesity has reached pandemic proportion not only in the West but also in other countries around the world; it is now one of the leading causes of death worldwide. A Western diet is rich in saturated fats and provides more calories than necessary, contributing to the rise of the obesity rate. It also promotes the development of liver steatosis, insulin resistance, hyperglycemia, and hyperlipidemia. In this issue of the JCI, Goetzman and colleagues describe the effects of consuming dicarboxylic acids (DAs) as an alternative source of dietary fat. The 12-carbon dicarboxylic acid (DC12) was administered to mice at 20% of their daily caloric intake for nine weeks in place of triglycerides. Notably, the change in diet increased the metabolic rate, reduced body fat, reduced liver fat, and improved glucose tolerance. These findings highlight DAs as useful energy nutrients for combatting obesity and treating various metabolic disorders.
Zachary A. Bacigalupa, Emily N. Arner, Logan M. Vlach, Melissa M. Wolf, Whitney A. Brown, Evan S. Krystofiak, Xiang Ye, Rachel A. Hongo, Madelyn Landis, Edith K. Amason, Kathryn E. Beckermann, W. Kimryn Rathmell, Jeffrey C. Rathmell
Satellite cells, the stem cells of skeletal muscle tissue, hold a remarkable regeneration capacity and therapeutic potential in regenerative medicine. However, low satellite cell yield from autologous or donor-derived muscles hinders the adoption of satellite cell transplantation for the treatment of muscle diseases, including Duchenne muscular dystrophy (DMD). To address this limitation, here we investigated whether satellite cells can be derived in allogeneic or xenogeneic animal hosts. First, injection of CRISPR/Cas9-corrected Dmdmdx mouse induced pluripotent stem cells (iPSCs) into mouse blastocysts carrying an ablation system of host satellite cells gave rise to intraspecies chimeras exclusively carrying iPSC-derived satellite cells. Furthermore, injection of genetically corrected DMD iPSCs into rat blastocysts resulted in the formation of interspecies rat-mouse chimeras harboring mouse satellite cells. Notably, iPSC-derived satellite cells or derivative myoblasts produced in intraspecies or interspecies chimeras restored dystrophin expression in DMD mice following intramuscular transplantation and contributed to the satellite cell pool. Collectively, this study demonstrates the feasibility of producing therapeutically competent stem cells across divergent animal species, raising the possibility of generating human muscle stem cells in large animals for regenerative medicine purposes.
Ajda Lenardič, Seraina A. Domenig, Joel Zvick, Nicola Bundschuh, Monika Tarnowska-Sengl, Regula Furrer, Falko No, Christine L. Trautmann, Adhideb Ghosh, Giada Bacchin, Pjeter Gjonlleshaj, Xhem Qabrati, Evi Masschelein, Katrien De Bock, Christoph Handschin, Ori Bar-Nur
59fb9ae87f